company background image
SLGC logo

Standard BioTools NasdaqGM:SLGC Stock Report

Last Price

US$2.10

Market Cap

US$396.2m

7D

-14.3%

1Y

-28.1%

Updated

09 Jan, 2024

Data

Company Financials +

Standard BioTools Inc.

NasdaqGM:SLGC Stock Report

Market Cap: US$396.2m

SLGC Stock Overview

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States.

SLGC fundamental analysis
Snowflake Score
Valuation0/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Standard BioTools Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Standard BioTools
Historical stock prices
Current Share PriceUS$2.10
52 Week HighUS$3.79
52 Week LowUS$1.73
Beta1.64
1 Month Change-13.93%
3 Month Change14.13%
1 Year Change-28.08%
3 Year Changen/a
5 Year Changen/a
Change since IPOn/a

Recent News & Updates

Recent updates

Why Investors Shouldn't Be Surprised By SomaLogic, Inc.'s (NASDAQ:SLGC) P/S

Dec 19
Why Investors Shouldn't Be Surprised By SomaLogic, Inc.'s (NASDAQ:SLGC) P/S

SomaLogic, Inc. (NASDAQ:SLGC) Just Reported, And Analysts Assigned A US$3.93 Price Target

Nov 10
SomaLogic, Inc. (NASDAQ:SLGC) Just Reported, And Analysts Assigned A US$3.93 Price Target

SomaLogic, Inc. (NASDAQ:SLGC) Stocks Shoot Up 33% But Its P/S Still Looks Reasonable

Apr 17
SomaLogic, Inc. (NASDAQ:SLGC) Stocks Shoot Up 33% But Its P/S Still Looks Reasonable

Downgrade: Here's How Analysts See SomaLogic, Inc. (NASDAQ:SLGC) Performing In The Near Term

Apr 02
Downgrade: Here's How Analysts See SomaLogic, Inc. (NASDAQ:SLGC) Performing In The Near Term

SomaLogic appoints former Foundation Medicine chief as executive chair

Oct 17

SomaLogic acquires Palamedrix to develop next-generation SomaScan Assay

Jul 26

We're Hopeful That SomaLogic (NASDAQ:SLGC) Will Use Its Cash Wisely

Jun 06
We're Hopeful That SomaLogic (NASDAQ:SLGC) Will Use Its Cash Wisely

SomaLogic Inc: A Biopharmaceutical Company With An Excellent Upside

Apr 12

Calculating The Intrinsic Value Of SomaLogic, Inc. (NASDAQ:SLGC)

Mar 09
Calculating The Intrinsic Value Of SomaLogic, Inc. (NASDAQ:SLGC)

We Think SomaLogic (NASDAQ:SLGC) Can Easily Afford To Drive Business Growth

Dec 28
We Think SomaLogic (NASDAQ:SLGC) Can Easily Afford To Drive Business Growth

SomaLogic: The Highest Number Of Proteins Analyzable In A Single Blood Sample In Proteomics

Oct 14

Shareholder Returns

SLGCUS Life SciencesUS Market
7D-14.3%-0.2%0.4%
1Y-28.1%4.5%28.8%

Return vs Industry: SLGC underperformed the US Life Sciences industry which returned -2.7% over the past year.

Return vs Market: SLGC underperformed the US Market which returned 21% over the past year.

Price Volatility

Is SLGC's price volatile compared to industry and market?
SLGC volatility
SLGC Average Weekly Movement11.4%
Life Sciences Industry Average Movement7.3%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: SLGC's share price has been volatile over the past 3 months.

Volatility Over Time: SLGC's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1999451Adam Taichhttps://www.somalogic.com

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company’s SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development.

Standard BioTools Inc. Fundamentals Summary

How do Standard BioTools's earnings and revenue compare to its market cap?
SLGC fundamental statistics
Market capUS$396.23m
Earnings (TTM)-US$130.38m
Revenue (TTM)US$81.72m

4.8x

P/S Ratio

-3.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SLGC income statement (TTM)
RevenueUS$81.72m
Cost of RevenueUS$97.89m
Gross Profit-US$16.16m
Other ExpensesUS$114.22m
Earnings-US$130.38m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.69
Gross Margin-19.78%
Net Profit Margin-159.54%
Debt/Equity Ratio0%

How did SLGC perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.